3'-Azido-3'-deoxythymidine β-D-glucuronide (sodium salt)
(Synonyms: 氮脱氧胸苷葡糖苷酸钠盐,AZT glucuronide,Zidovudine glucuronide) 目录号 : GC10387A zidovudine metabolite
Cas No.:133525-01-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3'-Azido-3'-deoxythymidine β-D-glucuronide is the metabolite of zidovudine, a nucleoside reverse transcriptase inhibitor.
Zidovudine, an antiretroviral medication used to prevent and treat HIV, is recommended for use with other antiretroviral and may be also used to prevent mother to child spread during birth or after a needlestick injury or other potential exposure.
In vitro: 3'-Azido-3'-deoxythymidine β-D-glucuronide is a metabolite of zidovudine, formed by direct conjugation by UDP-glucuronosyltransferase 2B7. The azido group of both zidovudine and 3'-azido-3'-deoxythymidine β-D-glucuronide could be reduced to an amino group by cytochrome CYP3A, CYP2A6, or CYP2B1, forming 3’-amino-3’-deoxythymidine (AMT) and AMT glucuronide, respectively [1].
In vivo: Animal study found that zidovudine-treated rats had higher systolic blood pressure, greater heart weight and greater interventricular septum thickness. Electron microscopy revealed mitochondrial swelling in myocardiocytes in zidovudine-treated rats. Reduced response to contractile stimuli and enhanced relaxation in response to charbacol were observed in the aortic rings of zidovudine-treated rats. The aortic myocytes of zidovudine-treated rats contained apparently unaffected ultrastructural features, but light microscopy suggested their marked enlargement [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Walsky, R. L.,Bauman, J.N.,Bourcier, K., et al. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metabolism and Disposition 40(5), 1051-1065 (2012).
[2] Ruga E, Bova S, Nussdorfer G, Mazzocchi G, Rebuffat P, Milanesi O, Cargnelli G. Zidovudine-induced alterations in the heart and vascular smooth muscle of the rat. Cardiovasc Res. 2003 Oct 15;60(1):147-55.
| Cas No. | 133525-01-6 | SDF | |
| 别名 | 氮脱氧胸苷葡糖苷酸钠盐,AZT glucuronide,Zidovudine glucuronide | ||
| 化学名 | 3'-azido-3'-deoxy-5'-O-β-D-glucopyranuronosyl-thymidine, monosodium salt | ||
| Canonical SMILES | O=C([O-])[C@@H](O1)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC[C@@H]2[C@@H](N=[N+]=[N-])C[C@H](N3C=C(C)C(NC3=O)=O)O2.[Na+] | ||
| 分子式 | C16H20N5O10 • Na | 分子量 | 465.4 |
| 溶解度 | ≤0.5mg/ml in DMSO | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1487 mL | 10.7434 mL | 21.4869 mL |
| 5 mM | 0.4297 mL | 2.1487 mL | 4.2974 mL |
| 10 mM | 0.2149 mL | 1.0743 mL | 2.1487 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。